Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.

Georgia Fogden-King's Articles

Driven by rapid growth Oxford Sciences Innovation expands to The Oxford Science Park

OSI builds on links with Park as second occupier of prestigious Schrödinger Building

Sustained Episomal Gene Expression Free from Foreign DNA

AMSBIO announces MC-Easy™ minicircle technology for labs looking to produce sustained transgene expression in model animal generation and gene therapy research without the risks of introducing exogenous DNA.

University of Birmingham to lead Midlands Innovation Commercialisation of Research Accelerator (MICRA)

The University of Birmingham is to lead a connected system of incubators and accelerators that will drive jobs and economic growth across the Midlands region, following a £5 million award announced today by Research England.

University spinouts – an imperfect ecosystem

The start of April marked the official launch of UK Research and Innovation (UKRI), an amalgamation of the seven research councils, Innovate UK and Research England. With this, UK universities’ ability to turn research into innovation is once again under the spotlight.

Edinburgh-based life science company, Neurocentrx have appointed two industry heavyweights to their board to help take the company to a global market

Neurocentrx are developing new uses and methods of administration for ketamine. Historically, ketamine has been used as an anaesthetic, but recent research shows this drug can also be used to help with pain management, such as required by cancer patients during treatment, and also psychiatric conditions such as depression.

Until now ketamine has not been suitable to treat these symptoms and conditions, but Neurocentrx are developing a new oral capsule format, that is easy to dose control, and can even be administered outside of a hospital environment, allowing countless more patients to be able to take advantage of the benefits this drug has now been proven to offer. 

Nigel Brooksby and Dr Tim Corn have both joined the board, bringing with them significant experience from their previous high-profile roles in the healthcare and pharmaceutical sector, so it’s fantastic to see Neorocentrx receiving this great support as the company reaches this exciting new phase.

Comprehensive Toolkit for Exosome Research

AMSBIO announces that its exosome product range now includes everything you need for studying and using exosomes, from isolation and characterization, to cargo profiling and engineering, and more. 

OBN Announce Utility Team as New Corporate Sponsor

Utility Team, who is one of the UK’s leading utilities and energy consultants, providing a wide range of value added utility has become one of their corporate sponsors.

AMSBIO Signs Global Agreement for Groundbreaking Myotube Technology

AMSBIO has signed an agreement with Genea Biocells (San Diego, USA) to become global distribution partner to the academic community for its groundbreaking skeletal muscle differentiation product range.

Novo Nordisk’s semaglutide spurs major weight loss in phase 2 obesity study

Novo Nordisk’s closely watched semaglutide has already shown it can spur weight loss in diabetic patients. Now it’s added evidence that it can help nondiabetic obesity patients shed pounds, too.

Oxford Nanopore Technologies Raises £100M in Funding

UK-based developer of a portable real-time DNA/RNA sequencer, raised £100M ($140M) in new funding.

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.